Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114689 | 1.00 | KDM4E (0.49) | KDM4EALDH1A1HRH3HTR7HRH2 | |
| Bromide SCHEMBL736690 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL14685579 | 0.88 | SIGMAR1 (0.41) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL2115306 | 0.88 | SIGMAR1 (0.41) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL13003 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL12449635 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL12449637 | 0.88 | KDM4E (0.51) | KDM4EALDH1A1HRH3HTR7 | |
| SCHEMBL9374424 | 0.88 | HRH3 (0.53) | KDM4EHRH3HTR7HRH2HRH1 | |
| SCHEMBL205774 | 0.82 | HRH3 (0.49) | KDM4EALDH1A1HRH3 | |
| SCHEMBL17277607 | 0.82 | KDM4E (0.55) | KDM4EALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-112004802-B | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | KDM4E 2022/4885ALDH1A1 1448/4885HRH3 1/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | KDM4E 2153/4885ALDH1A1 1370/4885HRH3 1/4885 |
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | KDM4E 1039/4885ALDH1A1 1242/4885HRH3 2/4885 |
| US-20210188808-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | KDM4E 2153/4885ALDH1A1 1370/4885HRH3 1/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | KDM4E 1674/4885ALDH1A1 1717/4885HRH3 3/4885 |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | KDM4E 2153/4885ALDH1A1 1370/4885HRH3 1/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | KDM4E 1674/4885ALDH1A1 1717/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.